Background
Results
C1772T | G1790A | C1772T and/or G1790A | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
Variable | N (%) | CC | CT + TT | p value | GG | GA + AA | p value | CC and GG | CC + TT and/or GA + AA | p value |
Age | ||||||||||
≥ 54 | 43 (48) | 33 | 10 | 0.571 | 41 | 2 | 0.474 | 31 | 12 | 0.518 |
< 54 | 46 (52) | 35 | 11 | 45 | 1 | 34 | 12 | |||
FIGO stage | ||||||||||
I and II | 70 (79) | 55 | 15 | 0.262 | 68 | 2 | 0.518 | 53 | 17 | 0.209 |
III and IV | 19 (21) | 13 | 6 | 18 | 1 | 12 | 7 | |||
Residual tumor | ||||||||||
Yes | 11 (12) | 9 | 2 | 0.493 | 10 | 1 | 0.330 | 8 | 3 | 0.616 |
No | 71 (88) | 59 | 19 | 76 | 2 | 57 | 21 | |||
Recurrence | ||||||||||
Yes | 23 (26) | 19 | 4 | 0.306 | 22 | 1 | 0.597 | 18 | 5 | 0.358 |
No | 66 (74) | 49 | 17 | 64 | 2 | 47 | 19 | |||
Death | ||||||||||
Yes | 15 (17) | 12 | 3 | 0.506 | 14 | 1 | 0.429 | 11 | 4 | 0.625 |
No | 74 (83) | 56 | 18 | 72 | 2 | 54 | 20 |
Univariate analysis | Multivariate analysis | |||||
---|---|---|---|---|---|---|
Variable | HR | 95% CI | p value | HR | 95% CI | p value |
C1772T | 0.762 | 0.215–2.701 | 0.674 | |||
G1790A | 1.609 | 0.211–12.28 | 0.647 | |||
C1772T and/or G1790A | 0.892 | 0.284–2.803 | 0.845 | |||
Age (> 54 vs ≤54) | 1.463 | 0.529–4.049 | 0.463 | |||
FIGO stage (III + IV vs I + II) | 15.62 | 4.949–49.31 | < 0.001 | 7.527 | 1.808–31.33 | 0.006 |
Residual tumor | 16.13 | 5.780–45.00 | < 0.001 | 4.030 | 1.127–14.41 | 0.032 |
Discussion
Type of cancer (Reference No.) | Case | Frequency (%) | Prognosis | ||
---|---|---|---|---|---|
C1772T | G1790A | C1772T | G1790A | ||
OCCC (present study) | 89 | 23.6 | 3.3 | No association | No association |
Colorectal cancer (21) | 336 | 20.6 | 2.7 | No association | No association |
Colorectal cancer (22) | 445 | 7.9 | 7.0 | No association | No association |
NSCLC (13) | 741 | 73.5 | 72.5 | CC has longer survival than CT and TT | No association |
NSCLC (14) | 285 | 46.3 | 47.4 | TT has shorter survival than CC and CT | AA has shorter survival than GG and GA |
Breast cancer (15) | 90 | 10.0 | 3.3 | C1772T polymorphism is associated with HIF-1α overexpression, found in patients with lymph node metastasis | No association |
Breast cancer (16) | 410 | 28.2 | 19.1 | T allele increases risk for lymph nodes metastasis | No association |
Prostate cancer (18) | 754 | 21.9 | NA | T allele increases risk for metastasis and resistance to ADT | NA |
RCC (23) | 160 | 90.0 | 55.5 | TT is earlier stage than the CC and CT | No association |
RCC (24) | 620 | 7.7 | 7.3 | No association | No association |
HNSCC (17) | 52 | 50.0 | 71.2 | T allele is more frequently found in patients with metastasis | GA and GG have shorter survival than AA |
OSCC (25) | 305 | 7.5 | 7.9 | No association | No association |
OSCC (26) | 74 | 18.6 | 37.5 | No association | A allele has shorter survival |
Thymic malignancy (27) | 57 | 14.9 | 0 | No association | NA |
Bladder cancer (19) | 219 | 10.0 | 6.8 | C1772T and/or G1790A polymorphic variants have shorter survival | |
Cervical cancer (28) | 162 | 14.2 | 6.8 | No association | No association |
Cervical cancer (29) | 199 | 11.1 | 6.0 | No association | No association |
Glioma (20) | 387 | 70.5 | 75.2 | CC has longer survival than CT and TT | No association |
Conclusion
Methods
Patient data and clinicopathological features (Table 4)
Variable | N (%) |
---|---|
Age | |
Median (range) | 54.4 (34–78) |
> 54 | 43 (48) |
≤ 54 | 46 (52) |
FIGO stage | |
I | 65 (73) |
II | 5 (6) |
III | 17 (19) |
IV | 2 (2) |
Treatment | |
OP only | 18 (20) |
OP+AC | 71 (80) |
Recurrence | |
Yes | 23 (26) |
No | 66 (74) |
Death | |
Yes | 15 (17) |
No | 74 (83) |